In addition to significant variation in clinical management of AIH across individual clinicians,(9) 38%‐93% of patients achieve complete biochemical remission,(10) up to 80% of patients experience a disease flare,(11) and up to 50% of patients develop cirrhosis.(12) A United Kingdom autoimmune hepatitis audit suggested that targeted therapeutic normalization of serum ALT at specific time points may not be an accurate longer term outcome marker and confirmed the clinical and diagnostic need for better noninvasive surrogate markers.(13). Here, GPT is linked to autoimmune hepatitis.